The priming induction regimen of HAG as a low dose chemotherapy strategy in AML clonal evolution

Sci China Life Sci. 2015 Dec;58(12):1302-5. doi: 10.1007/s11427-015-4974-5. Epub 2015 Nov 20.

Authors

AiLi Chen¹, JingYi Yang¹, ShaoYan Hu², Qian-Fei Wang³

Affiliations

¹ Key Laboratory of Genomic and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, 100101, China.
² The Children's Hospital of Soochow University, Suzhou, 215003, China. hsy139@126.com.
³ Key Laboratory of Genomic and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, 100101, China. wangqf@big.ac.cn.

PMID: 26588914
DOI: 10.1007/s11427-015-4974-5

No abstract available

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Clonal Evolution / drug effects*
Clonal Evolution / genetics
Cytarabine / administration & dosage
Dose-Response Relationship, Drug
Drug Resistance, Neoplasm / genetics
Granulocyte Colony-Stimulating Factor / administration & dosage
Harringtonines / administration & dosage
Homoharringtonine
Humans
Leukemia, Myeloid, Acute / drug therapy*
Leukemia, Myeloid, Acute / genetics
Treatment Outcome

Substances

Harringtonines
Cytarabine
Granulocyte Colony-Stimulating Factor
Homoharringtonine